Hepatitis C News and Research

Latest Hepatitis C News and Research

Case report on clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

3 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

Hard to Treat Diseases, Inc. and Shenzhen Mellow Hope announce, that the company commenced clinical trials for the company's Hepatitis A (brand name MEVAC-A) vaccine.

2 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

Hepatitis C investigations intensify as number of women infected by doctor rises

In recent news 12 women had been infected with the Hepatitis C virus allegedly from an anaesthetist Dr James Latham Peters, practising at an abortion clinic, Croydon Day Surgery. As the investigations continue the number of infected women has risen to 44.

1 Jun 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Nihal Altan-Bonnet, assistant professor of cell biology, Rutgers University in Newark, and her research team have made a significant new discovery about RNA viruses and how they replicate themselves.

29 May 2010

State roundup: Employees' insurance rates, a hospital merger, Florida and Mass. public health issues

Today's roundup of state news includes changes in insurance rates for Kansas state employees, problems with EMT certification in Massachusetts and a hospital merger in the Washington D.C. area.

29 May 2010

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

Infectious diseases specialist Dr Marc Pellegrini from the Walter and Eliza Hall Institute will today receive the Frank Fenner Award from the Australasian Society for Infectious Diseases, recognising Dr Pellegrini's efforts to understand human responses to chronic infections.

28 May 2010

New treatment benefits patients with advanced liver disease due to HCV infection: Researchers

Researchers at the UCLA Medical Center found that antiviral therapy during compensated cirrhosis, when compared with all other strategies, is the most cost-effective approach to treating patients with advanced liver disease due to hepatitis C infection. Full details appear in the June issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 May 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma.

From Roche Sequencing and Life Science 28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

HZI researchers develop new method to produce insulin for treatment of diabetes

More than eight million diabetics live in Germany. Diabetes is not restricted to our prosperous society and the highest growth rates often occur in countries with aspiring economies such as in Asia. Worldwide, more than 285 million people suffer from this illness; with 50 million diabetics, India is the country with the most people affected by this disease.

27 May 2010

Anadys Pharmaceuticals to raise $12.5 million through registered direct offering

Anadys Pharmaceuticals, Inc. announced today that it has entered into definitive agreements with certain institutional investors to raise approximately $12.5 million in gross proceeds in a "registered direct" offering through the sale of a total of 5,813,954 shares of its common stock at an offering price of $2.15 per share. Anadys estimates that net proceeds from the offering will be approximately $11.3 million, after deducting placement agents' fees and estimated offering expenses.

26 May 2010

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.

26 May 2010

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

Italian researchers have discovered that antiviral treatment and sustained virologic response prevents esophageal varices in patients with compensated hepatitis C -induced cirrhosis, indicating that endoscopic surveillance can be safely delayed or avoided in these patients. Full findings are published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

26 May 2010

MedMira obtains NHS Supply Chain listing for Reveal Rapid HIV Test in the UK

MedMira Inc., a developer of rapid diagnostic technology and solutions, today announced that the Company's Reveal Rapid HIV Test is now one of three rapid HIV tests listed by the National Health Services Supply Chain in the United Kingdom, and the only one able to address both point of care and laboratory testing requirements.

26 May 2010

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

A study conducted by researchers at the Cleveland Clinic finds that patients suffering from cirrhosis preceded by nonalcoholic steatohepatitis are at an equal risk of developing hepatocellular carcinoma than those who develop cirrhosis resulting from hepatitis C virus. Results of this study appear in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

26 May 2010

Hepatitis C News and Research

Latest Hepatitis C News and Research

Case report on clear cell ICC

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

HTDS commences clinical trials for MEVAC-A vaccine in Vietnam

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

Hepatitis C investigations intensify as number of women infected by doctor rises

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

State roundup: Employees' insurance rates, a hospital merger, Florida and Mass. public health issues

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

New treatment benefits patients with advanced liver disease due to HCV infection: Researchers

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

PCA-Rx represents next generation of chelation technology for ASD patients

HZI researchers develop new method to produce insulin for treatment of diabetes

Anadys Pharmaceuticals to raise $12.5 million through registered direct offering

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

MedMira obtains NHS Supply Chain listing for Reveal Rapid HIV Test in the UK

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Hepatitis C News and Research

Latest Hepatitis C News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in